Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 653Pancreatic Neoplasms 394Carcinoma, Hepatocellular 311Stomach Neoplasms 255Rectal Neoplasms 184Colonic Neoplasms 183Esophageal Neoplasms 174Carcinoma, Non-Small-Cell Lung 171Breast Neoplasms 152Neoplasms 135Neoplasm Metastasis 133Ovarian Neoplasms 124Cholangiocarcinoma 112Lung Neoplasms 110Liver Neoplasms 109Gastrointestinal Neoplasms 101Melanoma 88Biliary Tract Neoplasms 77Prostatic Neoplasms 76Endometrial Neoplasms 74Esophageal Squamous Cell Carcinoma 68Carcinoma, Renal Cell 57Sarcoma 56Squamous Cell Carcinoma of Head and Neck 54Uterine Cervical Neoplasms 51Head and Neck Neoplasms 47Adenocarcinoma Of Esophagus 47Urinary Bladder Neoplasms 42Triple Negative Breast Neoplasms 40Anus Neoplasms 36

Interventions

lenvatinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Gastrointestinal × 90 days × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡